OXT and depressive symptom measurement: Previous studies demonstrated that μ−opioid receptor blockade inhibits oxytocin-mediated antinociception [37] and that μ−opioid [38] and oxytocin [39] receptors are expressed in brain regions relevant to anxiety- and depression-like behavior, and are simultaneously modulated during development [40].